News - Actavis, Anti-virals, Regulation

Filter

Actavis confirms generic Exelon Patch patent challenge; InnoPharma debuts generic Vistide in USA

09-03-2013

US generics drugmaker Actavis (NYSE: ACT, formerly trading as Watson) confirmed that it has filed with…

ActavisAnti-viralsExelon PatchGenericsGilead SciencesInnoPharmaMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulationVistide

News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans; India revokes Pegasys patent

05-11-2012

Swiss drug major Novartis' (NOVN: VX) generics subsidiary Sandoz has initiated a Phase III clinical trial…

ActavisAnti-viralsAsia-PacificBaxter InternationalBiotechnologyGenericsHemobrasMarkets & MarketingNorth AmericaNovartisOncologyPatentsPegasysRegulationrFVIIIrituximabRocheSandozSouth AmericaWatson Pharmaceuticals

Back to top